abstract: OBJECTIVES: Treatment options for metastatic soft-tissue @entity242 are limited. The aim of this study was to investigate the clinical activity of @entity1260 rechallenge in @entity1352 ( @entity1352 ), @entity1821 ( @entity1821 ), @entity1822 ( @entity1822 ), and high-grade @entity242 not otherwise specified. METHODS: A retrospective search of the Royal Marsden @entity242 Unit Database was performed to identify @entity1 initially treated with @entity1260 (as single agent or in combination) and who were subsequently rechallenged with single-agent @entity1260 . Baseline demographics and response assessment were retrospectively obtained. RESULTS: Sixty-seven @entity1 were identified and the median age at diagnosis was 41 years (range, 18 to 71 y). There were 29 cases of @entity1352 , 17 of @entity1821 , 12 of @entity1822 , and 9 of @entity242 not otherwise specified. First-line @entity1260 -containing therapy was given to 14 @entity1 as adjuvant therapy (adjuvant group) and 53 @entity1 as palliative therapy (palliative group). Clinical activity (partial response or stable disease) with single-agent @entity1260 rechallenge was documented in 50.0% of @entity1 in the adjuvant group (7 in the second line) and 34.0% of @entity1 in the palliative group (15 in the second line, 1 in third line, and 2 in the fourth line). The median progression-free survival in @entity1 with documented clinical activity was 11.5 months (95% CI, 8.8-12.3) and 6.9 months (95% CI, 5.1-9.0), respectively, in the adjuvant and palliative group. @entity1260 rechallenge was mostly active in @entity1352 @entity1 (49.3%, 14 out of 29 @entity1 with partial remission or stable disease). CONCLUSIONS: @entity1260 rechallenge has clinical activity in soft-tissue @entity242 and can be considered a viable option in treating @entity3 .

title: Successful @entity1260 Rechallenge in Soft-Tissue XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'sarcomas', 'Sarcoma']

entities_list: @entity1352 :: ('MESH:D013584', 'Disease') :: ['SS', 'synovial sarcoma']

entities_list: @entity1822 :: ('MESH:D007890', 'Disease') :: ['leiomyosarcoma', 'LMS']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease']

entities_list: @entity1260 :: ('MESH:D007069', 'Chemical') :: ['Ifosfamide', 'ifosfamide']

entities_list: @entity1821 :: ('MESH:D008080', 'Disease') :: ['LPS', 'liposarcoma']

answer: @entity242 :: (MESH:D012509,Disease) :: ['Sarcoma']


abstract: BACKGROUND: Two large trials have reported contradictory results at 1 year after @entity715 aspiration in @entity583 ( @entity583 ). In a 1-year follow-up of the largest randomised trial of @entity715 aspiration, we aimed to clarify the longer-term benefits, to help guide clinical practice. METHODS: The trial of routine aspiration ThrOmbecTomy with PCI versus PCI ALone in @entity1 with @entity583 (TOTAL) was a prospective, randomised, investigator-initiated trial of routine manual thrombectomy versus percutaneous coronary intervention (PCI) alone in 10   732 @entity1 with @entity583 . Eligible adult @entity1 (aged >= 18 years) from 87 hospitals in 20 countries were enrolled and randomly assigned (1:1) within 12 h of symptom onset to receive routine manual thrombectomy with PCI or PCI alone. Permuted block randomisation (with variable block size) was done by a 24 h computerised central system, and was stratified by centre. @entity1 and investigators were not masked to treatment assignment. The trial did not show a difference at 180 days in the primary outcome of @entity65 , @entity583 , @entity1455 , or @entity712 . However, the results showed improvements in the surrogate outcomes of @entity1347 , but whether or not this finding would translate into a longer term benefit remained unclear. In this longer-term follow-up of the TOTAL study, we report the results on the primary outcome ( @entity65 , @entity583 , @entity1455 , or @entity712 ) and secondary outcomes at 1 year. Analyses of the primary outcome were by modified intention to treat and only included @entity1 who underwent index PCI. This trial is registered with ClinicalTrials.gov, number NCT01149044. FINDINGS: Between Aug 5, 2010, and July 25, 2014, 10   732 eligible @entity1 were enrolled and randomly assigned to thrombectomy followed by PCI (n=5372) or to PCI alone (n=5360). After exclusions of @entity1 who did not undergo PCI in each group (337 in the PCI and thrombectomy group and 331 in the PCI alone group), the final study population comprised 10   064 @entity1 (5035 thrombectomy and 5029 PCI alone). The primary outcome at 1 year occurred in 395 (8%) of 5035 @entity1 in the thrombectomy group compared with 394 (8%) of 5029 in the PCI alone group (hazard ratio [HR] 1  00 [95% CI 0  87-1  15], p=0  99). @entity65 within 1 year occurred in 179 (4%) of the thrombectomy group and in 192 (4%) of 5029 in the PCI alone group (HR 0  93 [95% CI 0  76-1  14], p=0  48). The key safety outcome, @entity64 within 1 year, occurred in 60 @entity1 (1  2%) in the thrombectomy group compared with 36 (0  7%) in the PCI alone group (HR 1  66 [95% CI 1  10-2  51], p=0  015). INTERPRETATION: Routine @entity715 aspiration during PCI for @entity583 did not reduce longer-term clinical outcomes and might be associated with an increase in @entity64 . As a result, @entity715 aspiration can no longer be recommended as a routine strategy in @entity583 . FUNDING: Canadian Institutes of Health Research, Canadian Network and Centre for Trials Internationally, and Medtronic Inc.

title: Outcomes after XXXX aspiration for @entity583 : 1-year follow-up of the prospective randomised TOTAL trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Participants']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'myocardial infarction', 'ST elevation myocardial infarction']

entities_list: @entity1347 :: ('MESH:C537775', 'Disease') :: ['ST segment resolution and distal embolisation']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity1455 :: ('MESH:D012770', 'Disease') :: ['cardiogenic shock']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular death', 'Cardiovascular death']

answer: @entity715 :: (MESH:D013927,Disease) :: ['thrombus']


abstract: OBJECTIVE: To explore the changes in serologic variables and clinical disease activity following B lymphocyte depletion in 22 @entity1 with @entity309 ( @entity309 ). METHODS: B lymphocyte depletion was attained using combination therapy based on the monoclonal anti- @entity2225 antibody rituximab. Levels of a serologic indicator of @entity32 , @entity1851 ( @entity1851 ), of antimicrobial antibodies, of autoantibodies including IgA-, IgM-, and IgG-class rheumatoid factors (RF), and of antibodies to cyclic citrullinated peptide (anti-CCP) were assayed. RESULTS: The majority of @entity1 showed a marked clinical improvement after treatment with rituximab, with benefit lasting up to 33 months. Levels of total serum immunoglobulins fell, although the mean values each remained within the normal range. Whereas the IgM-RF response paralleled the changes in total serum IgM levels, the levels of IgA-RF, IgG-RF, and IgG and anti-CCP antibodies decreased significantly more than did those of their corresponding total serum immunoglobulin classes. The kinetics for the reduction in @entity1851 levels also paralleled the decreases in autoantibody levels. In contrast, levels of antimicrobial antibodies did not change significantly. B lymphocyte return occurred up to 21 months posttreatment. The time to relapse after B lymphocyte return was often long and unpredictable (range 0-17 months). Relapse was, however, closely correlated with rises in the level of at least one autoantibody. Increased autoantibody levels were rarely observed in the absence of clinical change. CONCLUSION: Following B lymphocyte depletion in @entity1 with @entity309 , a positive clinical response occurred in correlation with a significant drop in the levels of @entity1851 and autoantibodies. Antibacterial antibody levels were relatively well maintained. B lymphocyte return preceded relapse in all @entity1 . There was also a temporal relationship between clinical relapse and rises in autoantibody levels. Although these observations are consistent with a role for B lymphocytes in the pathogenesis of @entity309 , the precise mechanisms involved remain unclear.

title: Serologic changes following B lymphocyte depletion therapy for XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']


abstract: The kappa-opioid receptor antagonist @entity14719 ( @entity14719 ) was recently shown to potentiate certain overt withdrawal signs in @entity1286 -dependent @entity35 . The present study sought to further assess this phenomenon by examining the influence of @entity14719 treatment upon the conditioned place aversion associated with the @entity1510 -precipitated @entity3347 . In addition, in vivo microdialysis studies were conducted in @entity1286 -dependent @entity35 to determine whether @entity14719 treatment can modify withdrawal-induced changes in basal @entity935 (DA) release within the mesolimbic system. @entity35 were pretreated with either saline or a single dose of @entity14719 and then received ascending doses of @entity1286 for 10 days. A @entity3347 was then precipitated by the administration of @entity1510 (1 mg/kg SC). In @entity35 which received chronic @entity1286 injections, administration of @entity1510 produced a characteristic @entity3347 and a marked aversion for an environment previously associated with @entity1510 -precipitated withdrawal. @entity14719 treatment potentiated most overt signs of @entity734 . This treatment also resulted in a greater withdrawal-induced place aversion. @entity1286 -dependent @entity35 exhibited a marked reduction in basal mesolimbic DA release. An even greater decrease in basal DA release was observed in @entity14719 treated @entity35 . These results suggest that endogenous kappa-systems are important in the modulation of mesolimbic DA release and the accompanying place aversion which occurs during opiate withdrawal.

title: Endogenous kappa-opioid systems in opiate withdrawal: role in aversion and accompanying changes in mesolimbic XXXX release.

entities_list: @entity3347 :: ('MESH:D013375', 'Disease') :: ['withdrawal syndrome']

entities_list: @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine']

entities_list: @entity14719 :: ('MESH:C051844', 'Chemical') :: ['nor-BNI', 'nor-binaltorphimine', 'Nor-BNI']

entities_list: @entity1510 :: ('MESH:D009270', 'Chemical') :: ['naloxone']

entities_list: @entity1286 :: ('MESH:D009020', 'Chemical') :: ['morphine', 'Morphine']

entities_list: @entity734 :: ('MESH:D019966', 'Disease') :: ['physical dependence']

answer: @entity935 :: (MESH:D004298,Chemical) :: ['dopamine']


abstract: Recruitment of basophils to sites of homocytotropic antibody-mediated @entity56 has been well documented in both experimental and clinical situations. Mechanisms underlying tissue basophil accumulation, however, remain unclear and may involve @entity6722 , cell proliferation, or both. We have recently reported the presence in @entity1 blood of circulating basophil/mast cell progenitors on the basis of @entity112 content of granulocyte colonies grown in methylcellulose. In the current studies we have analyzed the peripheral blood of 30 @entity1 with @entity402 and 25 comparable control subjects for frequency of basophil/mast cell progenitors by analysis of the @entity112 content of individual granulocyte colonies. Forty percent of granulocyte colonies in cultures of @entity1097 @entity1 contained @entity112 in comparison to only 11% in cultures of control subjects (p less than 0.001). @entity112 content per colony as well as mean @entity112 per cell in each colony was higher in granulocyte colonies of @entity1097 subjects and could not be related to colony size or culture conditions. Granulocyte colony growth was enhanced by antigen-stimulated, peripheral blood lymphomononuclear cell--conditioned media of @entity1097 @entity1 . @entity112 -positive colonies were found more frequently in active versus quiescent @entity66 (p less than 0.05). These results are consistent with the hypothesis that basophils accumulate at sites of @entity56 at least in part by recruitment of progenitors from circulation and subsequent differentiation in situ in response to lymphokines. Further studies by use of hemopoietic assays could elucidate the contribution of basophil production to the development of @entity56 .

title: Increased numbers of circulating basophil progenitors in XXXX @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['atopic disease']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic conditions', 'hypersensitivity reactions', 'allergic reactions']

entities_list: @entity112 :: ('MESH:D006632', 'Chemical') :: ['Histamine', 'histamine']

answer: @entity1097 :: (MESH:C566404,Disease) :: ['atopic']


abstract: INTRODUCTION: Recently, some authors have postulated the existence of the so-called <obsessive spectrum>. This would include disorders that have the common point of the presence of repetitive thoughts and actions, which may either have a <compulsive> or <impulsive> nature. Certain @entity16 with @entity717 have also been grouped within this spectrum, including some forms of @entity302 , @entity191 , @entity4790 or @entity2033 . There is evidence that physiopathological connections may exist between some of these conditions. METHODS: A case of a @entity1 with @entity2033 with obsessive signs and symptoms is presented. The @entity1 is a 50 year old male, diagnosed of @entity2033 who is being treated with 25 mg/day of @entity1088 and 10 mg/day of clorazepate. The @entity1 refused to eat certain foods for <fear of choking>. He began to display other @entity146 such as refusing to touch objects that might have been touched by others, and developed ritual checking methods. Treatment based on the administration of 40 mg/day of @entity903 was begun. With this treatment the compulsive symptoms have disappeared, as has the fear of choking. However, the @entity4790 typical of his condition persist and the signs and symptoms associated with a process of @entity303 are becoming increasingly evident. CONCLUSIONS: It is concluded that the case described may well be a good example of obsessive spectrum, and that the underlying physio-pathology should be studied.

title: [A case of obsessive symptoms in XXXX ].

entities_list: @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['obsessive behaviors']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity4790 :: ('MESH:D002819', 'Disease') :: ['choreic movements', "Sydenham's Chorea"]

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological disorders']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine']

entities_list: @entity2033 :: ('MESH:D006816', 'Disease') :: ["Huntington's Chorea", "Huntington's disease"]

entities_list: @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease"]

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['repetitive movements']

answer: @entity2033 :: (MESH:D006816,Disease) :: ['Huntington's disease']


abstract: Objectives. To explore the association between meditation and health related quality of life (HRQOL), @entity308 , @entity1295 , disability level, relapse rates, and disease activity in a large international sample of @entity1 with @entity15 ( @entity15 ). Methods. @entity1 were invited to take part in an online survey and answer questions relating to HRQOL, @entity308 , @entity1295 , disability, relapse rates, and their involvement in meditation practices. Results. Statistically and potentially clinically significant differences between those who meditated once a week or more and @entity1 who never meditated were present for mean mental health composite (MHC) scores, cognitive function scale, and health perception scale. The MHC results remained statistically significant on multivariate regression modelling when covariates were accounted for. Physical health composite (PHC) scores were higher in those that meditated; however, the differences were probably not clinically significant. Among those who meditated, fewer screened positive for @entity308 , but there was no relationship with @entity1295 or relapse rate. Those with worsened disability levels were more likely to meditate. Discussion. The study reveals a significant association between meditation, lower risk of @entity308 , and improved HRQOL in @entity1 with @entity15 .

title: Can meditation influence quality of life, XXXX , and disease outcome in @entity15 ? Findings from a large international web-based study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'people', 'Participants']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

answer: @entity308 :: (MESH:D003866,Disease) :: ['depression']


abstract: @entity61403 ( @entity61403 ) is a member of the BAF chromatin remodeling complex. Two isoforms have been described, namely DPF3a and DPF3b. The latter binds to acetylated and methylated @entity376 residues of histones. Here, we elaborate on the role of DPF3a and describe a novel pathway of cardiac gene transcription leading to pathological @entity1283 . Upon @entity1184 stimuli, casein kinase 2 phosphorylates @entity61403 a at @entity563 348. This initiates the interaction of DPF3a with the transcriptional repressors HEY, followed by the release of HEY from the DNA. Moreover, @entity23423 is bound by DPF3a, and is thus recruited to HEY genomic targets upon interaction of the two components. Consequently, the transcription of downstream targets such @entity15774 is initiated and pathological @entity1283 is established. In @entity1 , @entity61403 a is significantly up-regulated in @entity1184 hearts of @entity1 with @entity1121 or @entity472 . Taken together, we show that activation of DPF3a upon @entity1184 stimuli switches cardiac fetal gene expression from being silenced by HEY to being activated by @entity23423 . Thus, we present a novel pathway for pathological @entity1283 , whose inhibition is a long-term therapeutic goal for the treatment of the course of @entity712 .

title: Phosphorylation of the chromatin remodeling factor DPF3a induces XXXX through releasing HEY repressors from DNA.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity1184 :: ('MESH:D006984', 'Disease') :: ['hypertrophic']

entities_list: @entity1283 :: ('MESH:D006332', 'Disease') :: ['cardiac hypertrophy']

entities_list: @entity376 :: ('CHEBI:25094', 'Chemical') :: ['lysine']

entities_list: @entity1121 :: ('MESH:D002312', 'Disease') :: ['hypertrophic cardiomyopathy']

entities_list: @entity563 :: ('CHEBI:17822', 'Chemical') :: ['serine']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis']

answer: @entity1283 :: (MESH:D006332,Disease) :: ['cardiac hypertrophy']


abstract: @entity6 was observed in 29 of 448 @entity1 with thalassaemia major attending seven Italian centres. Twelve @entity1 , at onset of clinical @entity6 , presented with an asymptomatic @entity10200 , 13 with @entity1270 , and four with @entity1270 . All were diagnosed after 1979, at a mean age of 17 years. Mean age at diagnosis of @entity6 was lower in @entity1 born in the last two decades. In these @entity1 transfusions were started at a younger age and pre-transfusion haemoglobin concentration, serum ferritin concentration, incidence of @entity409 , and the presence of a family history of @entity6 were higher than in @entity1 born previously. Although 27 (93%) cases had @entity68 chelating treatment the mean serum ferritin concentration was 5600 micrograms/l; 25 (92%) of these @entity1 had signs of @entity409 . The determination of C peptide in 10 @entity1 showed a wide variation in pancreatic beta cell function, and insulin requirements ranged between 0.15 and 1.72 U/kg body weight. Metabolic control was generally poor. The onset of @entity6 was followed in most @entity1 by the appearance of other @entity299 , or both. Fourteen @entity1 died within three years of presenting with overt @entity6 . Haemosiderosis, @entity409 , and genetic factors seemed to be crucial in @entity6 development. Thalassaemic @entity1 developing clinical @entity6 are at high risk for other complications and should be strictly monitored, especially for @entity1374 .

title: Insulin dependent XXXX in thalassaemia.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes', 'Diabetes mellitus', 'diabetes mellitus']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver infections', 'liver disease', 'liver impairment']

entities_list: @entity10200 :: ('MESH:D006029', 'Disease') :: ['glycosuria']

entities_list: @entity1270 :: ('MESH:D007662', 'Disease') :: ['ketosis', 'ketoacidosis']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['endocrine or cardiac complications']

entities_list: @entity1374 :: ('MESH:D013959', 'Disease') :: ['thyroid impairment']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: Unusual forms and causes of @entity741 include @entity951 in the presence of normal coronary arteries ( @entity1112 ), @entity301 , @entity74 , and graft @entity731 after cardiac transplantation. There is now evidence that @entity409 of coronary resistance vessels can account for abnormalities of the coronary microvasculature and possibly, @entity741 and @entity662 . The incidence of @entity1112 appears to be higher in @entity1 , particularly those who have undergone hysterectomy. An intriguing hypothesis is that low @entity172 levels may be associated with reduced expression of @entity842 (reflecting @entity409 ). The presence of @entity301 in the young should not be underestimated. @entity1163 and @entity943 are observed frequently in this @entity1 population and warrant vigorous exploration. Worldwide, cardiac transplantation is now carried out in approximately 4500 @entity1 yearly, with excellent (80% to 90%) 1-year survival due to improved immunosuppression. However, accelerated @entity731 develops rapidly postoperatively and is the main cause of late death. The link between cellular rejection of the myocardium and transplant @entity453 is not clear. The process of transplant @entity453 is believed to be due to chronic @entity1200 followed by intimal smooth-muscle proliferation and lipid deposition in the vascular wall. By the time it is detected by coronary angiography, the disease is far advanced and not susceptible to routine revascularization procedures. A prospective, randomized study of @entity3988 versus no @entity460 blocker started early after transplantation has documented highly significant reductions in transplant @entity731 as measured by lumen narrowing, clinical events, and rates of retransplantation or death due to the process.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Unusual forms of XXXX .

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest pain']

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'women', 'patients']

entities_list: @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['congenital coronary abnormalities', 'coronary abnormalities']

entities_list: @entity1112 :: ('MESH:D040181', 'Disease') :: ['syndrome X']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction']

entities_list: @entity3988 :: ('MESH:D004110', 'Chemical') :: ['diltiazem']

entities_list: @entity1200 :: ('MESH:D007154', 'Disease') :: ['immune injury']

entities_list: @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['vasculitic disorders']

entities_list: @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease', 'myocardial ischemia']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['arrhythmias']

answer: @entity741 :: (MESH:D017202,Disease) :: ['ischemic heart disease']


abstract: Semen of @entity233 between 31 and 52 weeks of age was analyzed to investigate the cause of reduction in @entity233 fertility at the end of the reproductive period. Sperm motility and viability, lipid concentration, @entity844 composition and lipid @entity2627 were evaluated on fresh spermatozoa or spermatozoa stored for 48h at 4 degrees C. Fertility of fresh semen was also evaluated. Fertility obtained with fresh semen decreased at 44-47 weeks of age. Ageing was also accompanied by a decrease in sperm viability (at 47 weeks) and later by a decrease in motility of spermatozoa (at 52 weeks). @entity1474 ( @entity5204 ) were the first lipids of fresh spermatozoa affected by age, especially n-3 and n-9 @entity5204 . Changes in these @entity5204 were followed by a 30% increase in lipid peroxidation at 47 and 52 weeks of age and a reduction in phospholipid content at 52 weeks. In vitro storage did not cause lipid peroxidation in sperm obtained during the first half of the reproductive period but @entity1234 ( @entity1865 ) levels significantly increased in sperm obtained during the second half of this period. In vitro storage also decreased phospholipid content of spermatozoa from 41 weeks of age, and viability and motility regardless of age. In conclusion, lipid alteration mainly originating from @entity5204 peroxidation could partly explain the decrease in semen quality and fertility observed with ageing. In addition, lipid peroxidation was increased during in vitro storage of spermatozoa from older @entity233 .

title: Reproductive period affects lipid composition and quality of fresh and stored spermatozoa in XXXX .

entities_list: @entity844 :: ('CHEBI:35366', 'Chemical') :: ['fatty acid']

entities_list: @entity2627 :: ('MESH:D010545', 'Chemical') :: ['peroxides']

entities_list: @entity233 :: ('9103', 'Species') :: ['Turkey', 'Turkeys']

entities_list: @entity1474 :: ('MESH:D005231', 'Chemical') :: ['Polyunsaturated fatty acids']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

answer: @entity233 :: (9103,Species) :: ['Turkeys']


abstract: Autoantibodies against nucleosomes are considered a hallmark of @entity1252 ( @entity1252 ). We compared in @entity1 with proliferative @entity1988 the diagnostic usefulness of a dsDNA-loaded nucleosome ELISA (anti-dsDNA- @entity43635 ) with ELISAs in which dsDNA or nucleosomes alone were coated. First, we analysed whether DNA loading on nucleosomes led to masking of epitopes by using defined monoclonal anti-DNA, anti-histone and nucleosome-specific autoantibodies to evaluate the accessibility of nucleosomal epitopes in the anti-dsDNA- @entity43635 ELISA. Second, autoantibody levels were measured in these 3 ELISAs in 100 @entity1 with proliferative @entity1988 ( @entity1988 ) before immunosuppressive treatment and in 128 non- @entity1252 disease controls. In @entity1 with @entity1988 inter-assay comparisons and associations with clinical and serological parameters were analysed. The panel of monoclonal antibodies revealed that all epitopes were equally accessible in the anti-dsDNA- @entity43635 ELISA as in the two other ELISAs. @entity1 with proliferative @entity1988 were positive with dsDNA-loaded nucleosomes in 86%, with DNA in 66% and with nucleosomes in 85%. In the @entity1252 control group these frequencies were 1.6% (2 out of 128) for both the anti-dsDNA- @entity43635 and the anti-dsDNA ELISA and 0% in the anti-nucleosome ELISA. The levels in the anti-dsDNA- @entity43635 ELISA were high in a group of @entity1 with @entity1988 that showed absent reactivity in the anti-DNA or low levels in the anti-nucleosome ELISA. Anti-dsDNA- @entity43635 positivity was associated with higher SLEDAI scores within this group. Within nucleosome-based ELISAs, we propose the anti-dsDNA- @entity43635 ELISA as the preferred test system.

title: Reactivity in ELISA with DNA-loaded nucleosomes in @entity1 with proliferative XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['lupus nephritis', 'LN']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['SLE', 'systemic lupus erythematosus', 'non-lupus disease']

answer: @entity1988 :: (MESH:D008181,Disease) :: ['lupus nephritis']


abstract: @entity2449 (MET) is known to increase several biological effects of insulin (INS), but there is no information concerning its direct effects on protein synthesis. We studied the action of MET on albumin production by primary cultures of freshly isolated @entity35 hepatocytes, alone or in combination with various agonists: INS, @entity2135 , EGF, thyroxin, and @entity619 . While having no effect alone, MET in vitro potentiates the effects of INS, @entity2135 , and EGF. When this increasing effect toward INS was studied over a broad concentration range, MET appeared to improve low-acting INS levels and to intensify the maximal INS effects. In contrast, MET did not change the production of albumin stimulated by thyroxin or @entity619 . Animals chronically pretreated with MET in vivo showed a higher yield of isolated hepatocytes, better attachment, and especially higher viability after liver perfusion and during cell culture. This may largely explain why basal albumin rates were higher than in in vitro-treated cells. The effect of MET in the presence of the agonists exhibited the same agonist-specificity as in vitro. Our data provide new insights into the pharmacology of MET by showing that hepatic protein synthesis is increased by MET and INS. From the specificity of action of MET towards INS, @entity2135 , and EGF (but not thyroxin or @entity619 ), we hypothesize that this @entity28943 may act on intracellular pathways located between membrane receptors and sites of branching in the signaling cascades shared by these agonists.

title: @entity2449 induces an agonist-specific increase in albumin production by primary cultured XXXX hepatocytes.

entities_list: @entity28943 :: ('CHEBI:3095', 'Chemical') :: ['biguanide']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The @entity9887 Effectiveness on Left ventricular MAss Reduction (TELMAR) trial will assess the effect of the angiotensin II (Ang II) receptor blocker, @entity9887 , on @entity4346 ( @entity4346 ) compared with the b-blocker, @entity1406 , at similar antihypertensive doses. The rationale is that antihypertensives reduce @entity4346 , a cardiac adaptation to pressure overload, principally by pressure-related effects. Ang II plays a key role in pressure-independent mechanisms causing @entity4346 , and @entity1289 ( @entity1289 ) inhibitors induce more pronounced @entity4346 regression than some other antihypertensives. Blocking Ang II Type 1 receptors may be more effective than @entity1289 inhibition in reducing @entity4346 . TELMAR is a prospective, randomised, double-blind, double-dummy, parallel-group trial. A total of 140 @entity1 (age 18 80 years) with uncontrolled essential @entity101 (mean daytime systolic blood pressure [SBP] >140 mmHg or diastolic blood pressure [DBP] >90 mmHg and/or night-time SBP >120 mmHg or DBP >70 mmHg, measured by ambulatory blood pressure monitoring [ABPM]) and left ventricular mass index related to height (LVMI) >0.8 g/cm for females, >1.1 g/cm for males (defined by magnetic resonance imaging [MRI]) will be randomised to once-daily @entity9887 or @entity1406 . The @entity9887 dose will be 40 mg for the first two weeks, 80 mg for 5.5 months and 40 mg for the last two weeks. @entity1406 will be given at a dose of 47.5 mg for two weeks, 95 mg for 5.5 months and 47.5 mg for two weeks. Concomitant add-on medication with @entity918 and @entity3591 will be allowed. The primary endpoint is the percentage change in LVMI at treatment end versus baseline, using MRI. Secondary variables include blood pressure changes and response rates assessed by ABPM and manual cuff sphygmomanometry, and end-systolic wall stress, systolic @entity1002 ( @entity1002 ) and diastolic @entity1002 determined by MRI. A separate study was performed prior to the main trial to define the normal range of MRI data in an age-matched population.

title: Reduction (TELMAR) as assessed by magnetic resonance imaging in @entity1 with mild-to-moderate @entity101 --a prospective, randomised, double-blind comparison of XXXX with @entity1406 over a period of six months rationale and study design.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['ACE', 'angiotensin-converting enzyme']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity918 :: ('MESH:D006852', 'Chemical') :: ['hydrochlorothiazide']

entities_list: @entity1406 :: ('MESH:D008790', 'Chemical') :: ['Metoprolol', 'metoprolol']

entities_list: @entity4346 :: ('MESH:D017379', 'Disease') :: ['LVH', 'left ventricular hypertrophy']

entities_list: @entity3591 :: ('MESH:D017311', 'Chemical') :: ['amlodipine']

entities_list: @entity9887 :: ('MESH:C084178', 'Chemical') :: ['Telmisartan', 'telmisartan']

entities_list: @entity1002 :: ('MESH:D018487', 'Disease') :: ['left ventricular function', 'LVF']

answer: @entity9887 :: (MESH:C084178,Chemical) :: ['telmisartan']


abstract: OBJECTIVES: Several methods for measuring @entity6579 ( @entity15002 ) concentrations have been reported. However, these methods are not practical because they are either too complicated and/or too time-consuming for @entity15002 determinations in human serum and plasma. DESIGN AND METHODS: We have developed a new enzymatic @entity15002 assay, which uses lysophospholipase, @entity11834 phosphodiesterase and @entity1877 oxidase, and which determines the quantities of @entity273 generated in the presence of peroxidase using an oxidative chromogenic reagent and @entity23134 . RESULTS: Various samples were mixed with @entity15002 assay reagents, and their changes in absorbance were measured. The present method produced a linear calibration line between @entity15002 concentration and absorbance change. It also measured only @entity15002 , and not other phospholipids such as @entity2434 , @entity4291 and @entity4990 . The within-run and between-run coefficients of variation were 0.3-0.7% and 0.7%, respectively. The recovery of exogenous @entity15002 added to control serum was 99.5-102.1%. The correlation coefficient obtained in a comparison with a method for analyzing @entity1718 was 0.9122. CONCLUSIONS: The present method is simple, specific for @entity15002 , and can be applied with an automatic analyzer. It may also be useful for further studies of the biological functions of @entity15002 as well as clinical applications in various disorders.

title: An enzymatic assay for XXXX concentration in human serum and plasma.

entities_list: @entity4990 :: ('MESH:C032881', 'Chemical') :: ['lysophosphatidic acid']

entities_list: @entity6579 :: ('MESH:D008244', 'Chemical') :: ['lysophosphatidylcholine']

entities_list: @entity11834 :: ('MESH:D005997', 'Chemical') :: ['glycerophosphorylcholine']

entities_list: @entity2434 :: ('MESH:D010713', 'Chemical') :: ['phosphatidylcholine']

entities_list: @entity273 :: ('MESH:D006861', 'Chemical') :: ['hydrogen peroxide']

entities_list: @entity23134 :: ('MESH:D000675', 'Chemical') :: ['4-aminoantipyrine']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity4291 :: ('CHEBI:17636', 'Chemical') :: ['sphingomyelin']

answer: @entity6579 :: (MESH:D008244,Chemical) :: ['lysophosphatidylcholine']


abstract: BACKGROUND: Lowering the blood @entity165 level may reduce the risk of @entity301 . This double-blind study was designed to determine whether the administration of @entity8673 to @entity1 with @entity1007 and no history of @entity583 reduced the combined incidence of nonfatal @entity583 and @entity204 from @entity301 . METHODS: We randomly assigned 6595 @entity1 , 45 to 64 years of age, with a mean (+/- SD) plasma @entity165 level of 272 +/- 23 mg per deciliter (7.0 +/- 0.6 mmol per liter) to receive @entity8673 (40 mg each evening) or placebo. The average follow-up period was 4.9 years. Medical records, electrocardiographic recordings, and the national @entity204 registry were used to determine the clinical end points. RESULTS: @entity8673 lowered plasma @entity165 levels by 20 percent and low-density-lipoprotein @entity165 levels by 26 percent, whereas there was no change with placebo. There were 248 definite coronary events (specified as nonfatal @entity583 or @entity204 from @entity301 ) in the placebo group, and 174 in the @entity8673 group (relative reduction in risk with @entity8673 , 31 percent; 95 percent confidence interval, 17 to 43 percent; P < 0.001). There were similar reductions in the risk of definite nonfatal @entity583 (31 percent reduction, P < 0.001), @entity204 from @entity301 (definite cases alone: 28 percent reduction, P = 0.13; definite plus suspected cases: 33 percent reduction, P = 0.042), and @entity204 from all cardiovascular causes (32 percent reduction, P = 0.033). There was no excess of deaths from noncardiovascular causes in the @entity8673 group. We observed a 22 percent reduction in the risk of @entity204 from any cause in the @entity8673 group (95 percent confidence interval, 0 to 40 percent; P = 0.051). CONCLUSIONS: Treatment with @entity8673 significantly reduced the incidence of @entity583 and @entity204 from cardiovascular causes without adversely affecting the risk of @entity204 from noncardiovascular causes in @entity1 with moderate @entity1007 and no history of @entity583 .

title: Prevention of XXXX with @entity8673 in @entity1 with @entity1007 . West of Scotland Coronary Prevention Study Group.

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary heart disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarctions', 'myocardial infarction']

entities_list: @entity8673 :: ('MESH:D017035', 'Chemical') :: ['Pravastatin', 'pravastatin']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity301 :: (MESH:D003327,Disease) :: ['coronary heart disease']


abstract: CONTEXT: Pituitary surgery is the first line of treatment for @entity699 ; when surgery fails, bilateral adrenalectomy may be proposed, particularly for @entity1 with a desire for pregnancy. Little is known about the impact of pregnancy on corticotroph @entity5 progression after bilateral adrenalectomy. OBJECTIVE: The aim was to evaluate the impact of pregnancy on corticotroph @entity5 progression after bilateral adrenalectomy in @entity699 and to assess maternal and pregnancy outcomes. DESIGN: We conducted a retrospective cohort study. SETTING: @entity1 who became pregnant after bilateral adrenalectomy were followed in a single center. @entity1 : Twenty pregnancies from 11 @entity1 with @entity699 were treated by bilateral adrenalectomy and no pituitary irradiation. MEASUREMENTS: Corticotroph @entity5 progression was assessed by serial pituitary magnetic resonance imaging and plasma @entity4545 measurements before, during, and after pregnancy. Comparisons were performed using paired Wilcoxon rank tests. Data on maternal and neonatal outcomes were recorded by correspondence from @entity1 and obstetricians. RESULTS: Corticotroph @entity5 progression occurred in eight of 17 pregnancies, and @entity4545 increased in eight of 10 pregnancies. However, rates of increase during or after pregnancy were not faster than those observed before pregnancy. @entity532 occurred in four pregnancies from two @entity1 , including gestational @entity101 in three and @entity6 in three. Among these four pregnancies, three had a favorable outcome, and one led to an in utero @entity204 after @entity3036 , due to loss to follow-up. No other @entity2241 were reported. CONCLUSION: Pregnancy does not accelerate corticotroph @entity5 progression after bilateral adrenalectomy. Pregnancy is manageable, provided the @entity1 can be followed closely.

title: Pregnancy does not accelerate corticotroph XXXX progression in Nelson's syndrome.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'PATIENTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['gestational diabetes mellitus']

entities_list: @entity532 :: ('MESH:D003925', 'Disease') :: ['Maternal complications']

entities_list: @entity699 :: ('MESH:D003480', 'Disease') :: ["Cushing's disease"]

entities_list: @entity3036 :: ('MESH:D004461', 'Disease') :: ['eclampsia']

entities_list: @entity2241 :: ('MESH:D005315', 'Disease') :: ['maternal or fetal complications']

answer: @entity5 :: (MESH:D009369,Disease) :: ['tumor']


abstract: The insulinlike growth factor signaling axis (factors I and II and their receptor) has been implicated in hepatocarcinogenesis. Previous studies on insulinlike growth factor I receptor using resected @entity157 generated mixed results; however, the distribution and clinical significance of insulinlike growth factor I receptor b expression in @entity157 in the setting of liver transplantation have not been evaluated. Immunohistochemical staining for insulinlike growth factor I receptor b was performed in 72 liver explants from @entity1 with @entity157 undergoing liver transplantation. Expression of insulinlike growth factor I receptor b in hepatocytes was noted in 59.7% of @entity5 but only 6.9% of adjacent, nontumorous liver tissues (P < .001). Compared with subjects with @entity5 within Milan criteria, those who fell beyond had 3.1 times higher odds of having insulinlike growth factor I receptor b-positive @entity5 (95% confidence interval, 1.003-9.8). Poorly differentiated @entity157 had 10.3 times higher odds of insulinlike growth factor I receptor b positivity compared with well- or moderately differentiated @entity5 (95% confidence interval, 1.3-85.2). Subjects with @entity1561 were less likely to have insulinlike growth factor I receptor b-positive @entity5 (P = .015). Finally, higher arteriolar insulinlike growth factor I receptor b scores in the @entity5 and adjacent liver were significantly associated with insulinlike growth factor I receptor b expression in @entity5 cells (P = .015 and .043 for intratumoral and adjacent arterioles, respectively) in a subset of 26 randomly chosen @entity157 . Our results suggest that synchronized up-regulation of the insulinlike growth factor I receptor axis in @entity5 cells and intratumoral and adjacent arterioles could represent a mechanism of hepatocarcinogenesis and progression as manifest by poor differentiation and @entity5 beyond Milan criteria. Targeted therapies against insulinlike growth factor receptors may be justifiable in the treatment of @entity157 .

title: Insulin-like growth factor I receptor b expression in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma', 'hepatocellular carcinomas']

entities_list: @entity1561 :: ('MESH:D065626', 'Disease') :: ['nonalcoholic steatohepatitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: Previous studies in gerbils have shown that cytoskeletal disruption and a loss of the dendritic microtubule-associated protein, @entity19744 , may occur after short periods of transient global @entity63 . tau, a predominantly axonal microtubule-associated protein, has not been examined following @entity63 . We compared neuronal damage with alterations in @entity19744 , tau, and 72-kD @entity19514 ( @entity34445 ) immunostaining at various reperfusion times following 20 min of @entity63 in the @entity35 four-vessel occlusion model. tau accumulated in neuronal cell bodies throughout the hippocampal formation 30 min to 2 h after the @entity63 insult. Perikaryal tau immunostaining was transient in most regions, but persisted in polymorphic hilar neurons. This was accompanied by a loss of immunostaining in the target of many hilar neurons, the inner molecular layer of the dentate gyrus. The same neuronal populations that exhibited increased tau immunostaining of perikarya later displayed an induction of @entity34445 immunoreactivity. In contrast, loss of @entity19744 immunostaining was not consistently observed before @entity528 and did not correspond to @entity34445 induction. The altered tau immunostaining is not the direct result of excitotoxic insult, as intrahippocampal injection of @entity4176 did not cause the somal accumulation of tau, but did cause disruption of @entity19744 immunostaining. Taken together, the results suggest that the somal accumulation of tau is an early, sensitive, and selective marker of @entity63 insult.

title: Alterations in tau immunostaining in the XXXX hippocampus following transient cerebral ischemia.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity4176 :: ('MESH:D007608', 'Chemical') :: ['kainic acid']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal death']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: PURPOSE: Ultrasound-guided fine needle aspirate cytology fails to diagnose many malignant thyroid nodules; consequently, @entity1 may undergo diagnostic lobectomy. This study assessed whether textural analysis (TA) could noninvasively stratify thyroid nodules accurately using diffusion-weighted MRI (DW-MRI). METHODS: This multi-institutional study examined 3T DW-MRI images obtained with spin echo echo planar imaging sequences. The training data set included 26 @entity1 from Cambridge, United Kingdom, and the test data set included 18 @entity259 @entity1 from Memorial Sloan Kettering Cancer Center (New York, New York, USA). Apparent diffusion coefficients (ADCs) were compared over regions of interest (ROIs) defined on thyroid nodules. TA, linear discriminant analysis (LDA), and feature reduction were performed using the 21 MaZda-generated texture parameters that best distinguished benign and malignant ROIs. RESULTS: Training data set mean ADC values were significantly different for benign and malignant nodules (P   =   0.02) with a sensitivity and specificity of 70% and 63%, respectively, and a receiver operator characteristic (ROC) area under the curve (AUC) of 0.73. The LDA model of the top 21 textural features correctly classified 89/94 DW-MRI ROIs with 92% sensitivity, 96% specificity, and an AUC of 0.97. This algorithm correctly classified 16/18 (89%) @entity1 in the independently obtained test set of thyroid DW-MRI scans. CONCLUSION: TA classifies thyroid nodules with high sensitivity and specificity on multi-institutional DW-MRI data sets. This method requires further validation in a larger prospective study. Magn Reson Med, 2015.    2015 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Magn Reson Med 75:1708-1716, 2016.    2015 The Authors. Magnetic Resonance in Medicine published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance.

title: Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected XXXX on diffusion-weighted MRI.

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

answer: @entity259 :: (MESH:D013964,Disease) :: ['thyroid tumors']


abstract: BACKGROUND: Current evidence suggests that local anesthetic wound infiltration should be employed as part of multimodal @entity282 management. There is scarce data concerning the benefits of this anesthetic modality in laparoscopic weight loss surgery. Therefore, we analyzed the influence of trocar site infiltration with @entity1341 on the management of @entity282 in laparoscopic bariatric surgery. METHODS: This retrospective randomized study included 47 @entity1 undergoing primary @entity28 surgery between January and September 2014. Laparoscopic gastric bypass was performed in 39 cases and sleeve gastrectomy in 8 cases. @entity1 were stratified into two groups depending on whether preincisional infiltration with @entity1341 and @entity1425 was performed (study group, 27 @entity1 ) or not (control group, 20 @entity1 ). Visual analogue scale (VAS), International @entity158 Outcomes questionnaire, and rescue medication records were reviewed to assess @entity282 . RESULTS: VAS scores in the study group and sleeve gastrectomy group were lower than those in the control and gastric bypass groups in the first 4  h postoperatively without reaching statistical significance (p   >   0.05). VAS scores did not differ in any other period of time. No statistically significant differences in @entity158 perception were registered according to the @entity1 's @entity158 outcomes questionnaire or the need for rescue medication. CONCLUSIONS: The present study did not conclusively prove the efficacy of @entity1341 infiltration by any of the three evaluation methods analyzed. Nevertheless, preincisional infiltration provides good level of comfort in the immediate postoperative period when @entity1337 is most urgent.

title: Does Preincisional Infiltration with XXXX Reduce @entity282 in Laparoscopic Bariatric Surgery?

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['epinephrine']

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity1341 :: ('MESH:D002045', 'Chemical') :: ['bupivacaine']

entities_list: @entity282 :: ('MESH:D010149', 'Disease') :: ['postoperative pain']

answer: @entity1341 :: (MESH:D002045,Chemical) :: ['Bupivacaine']


abstract: AIM: To analyze prognostic factors for survival after transarterial chemoembolization (TACE) combined with microwave ablation (MWA) for @entity157 ( @entity157 ). METHODS: Clinical data of 86 @entity1 who underwent TACE combined with MWA between January 2006 and December 2013 were retrospectively analyzed in this study. Survival curves were detected using log-rank test. Univariate analysis was performed using log-rank test with respect to 13 prognostic factors affecting survival. All statistically significant prognostic factors identified by univariate analysis were entered into a Cox proportion hazards regression model to identify independent predictors of survival. P values were two-sided and P < 0.05 was considered statistically significant. RESULTS: Median follow-up time was 47.6 mo, and median survival time of enrolled @entity1 was 21.5 mo. The 1-, 2-, 3- and 5-year overall survival rates were 72.1%, 44.1%, 31.4% and 13.9%, respectively. @entity5 size(  (2) = 14.999, P = 0.000), @entity96 ( @entity96 ) stage (  (2) = 29.765, P = 0.000), @entity1 -Pugh class (  (2) = 51.820, P = 0.000), portal vein @entity5 thrombus (PVTT) (  (2) = 43.086, P = 0.000), @entity7838 (  (2) = 29.791, P = 0.000), MWA therapy times (  (2) = 12.920, P = 0.002), Eastern Cooperative Oncology Group (ECOG) score (  (2) = 28.660, P = 0.000) and targeted drug usage (  (2) = 10.901, P = 0.001) were found to be significantly associated with overall survival by univariate analysis. Multivariate analysis identified that @entity5 size (95%CI: 1.608-4.962, P = 0.000), @entity96 stage (95%CI: 1.016-2.208, P = 0.020), PVTT (95%CI: 2.062-9.068, P = 0.000), MWA therapy times (95%CI: 0.402-0.745, P = 0.000), ECOG score (95%CI: 1.012-3.053, P = 0.045) and targeted drug usage (95%CI: 1.335-3.143, P = 0.001) were independent prognostic factors associated with overall survival. CONCLUSION: Superior performance status, MWA treatment and targeted drug were favorable factors, and large @entity157 , PVTT and advanced @entity96 stage were risk factors for survival after TACE-MWA for @entity157 .

title: Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Child', 'patients']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['Barcelona Clinic Liver Cancer', 'BCLC']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity7838 :: ('MESH:D001159', 'Disease') :: ['arterio-venous fistula']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: During the gradual removal of @entity4 with diuretics in 21 @entity4 @entity1 with the @entity1985 ( @entity1985 ) we monitored blood volume. For comparison, nine healthy subjects were studied after equilibration on diets containing 20, 200, and 1138 mEq @entity1372 . The initial extracellular fluid volume (ECFV) in the @entity1 exceeded the final ECFV by 63.4 +/- 8.4%. In 10 @entity1 with a very low plasma oncotic pressure (8.2 +/- 0.4 mm Hg, Group 1), the blood volume changed little. In Group 2 (plasma oncotic pressure 13.4 +/- 1.0 mm Hg), it was 11.0 +/- 2.5% higher at entry than after @entity4 withdrawal. In the normal volunteers, the highest @entity1372 intake raised the ECFV by 21.4 +/- 4.1%. The accompanying rise in blood volume, 11.2 +/- 3.0%, was larger than in the @entity1 of Group 1 (2.4 +/- 1.9%, P less than 0.04), but not of Group 2 (8.1 +/- 1.9%, @entity1985 ) at similar degrees of expansion. There was no difference in blood volume between the @entity4 -free @entity1 and the normal subjects at low- @entity1372 diet. The course of blood pressure and @entity1011 clearance during @entity4 removal gave no evidence that functional @entity3485 was induced, but the plasma @entity916 activity was higher than in the normal subjects at similar degrees of expansion. We conclude that the blood volume to ECFV relationship curve is flattened in the presence of @entity4988 . Thus, the increase in blood volume that normally follows ECFV expansion is less in @entity1 with the @entity1985 , but a drop below normal upon removal of @entity4 is absent also.

title: Preservation of blood volume during @entity4 removal in XXXX subjects.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity4988 :: ('MESH:D034141', 'Disease') :: ['hypoalbuminemia']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['edematous', 'edema']

entities_list: @entity3485 :: ('MESH:D020896', 'Disease') :: ['hypovolemia']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1985 :: ('MESH:D009404', 'Disease') :: ['NS', 'nephrotic syndrome']

answer: @entity1985 :: (MESH:D009404,Disease) :: ['nephrotic']


abstract: BACKGROUND: @entity470 ( @entity470 ) is overexpressed in a significant proportion of esophageal and @entity356 . Although previous studies have examined @entity669 kinase inhibitors of @entity470 , there remains limited data regarding the role of @entity470 -directed monoclonal antibody therapy in these @entity5 . We carried out a multi-institutional phase II study of cetuximab, a monoclonal antibody against @entity470 , in @entity1 with unresectable or metastatic esophageal or @entity356 . @entity1 AND METHODS: Thirty-five @entity1 with previously treated metastatic esophageal or @entity356 were treated with weekly cetuximab, at an initial dose of 400 mg/m(2) followed by weekly infusions at 250 mg/m(2). @entity1 were followed for @entity137 , treatment response, and survival. RESULTS: Treatment with cetuximab was well tolerated; no @entity1 were taken off study due to drug-related adverse events. One (3%) partial treatment response was noted. Two (6%) @entity1 had stable disease after 2 months of treatment. Median progression-free survival and overall survival were 1.6 and 3.1 months, respectively. CONCLUSION: Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in @entity1 with metastatic esophageal and @entity356 . Ongoing studies of @entity470 inhibitors in combination with other agents may define a role for these agents in the treatment of esophageal and @entity356 .

title: A multicenter phase II trial of single-agent cetuximab in advanced esophageal and XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity470 :: ('1956', 'Gene') :: ['Epidermal growth factor receptor', 'EGFR']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancies']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer', 'gastric adenocarcinoma', 'gastric carcinomas']

answer: @entity356 :: (MESH:D013274,Disease) :: ['gastric adenocarcinoma']


abstract: A large number of @entity1 mononuclear cells were simultaneously separated into fractions enriched in B cells, T cells, large granular lymphocytes (LGL) and monocytes by centrifugal elutriation. Lymphocyte populations were analyzed using monoclonal antibodies. In particular, highly enriched natural killer cells, @entity4755 + cells, were collected in the intermediate fractions. Monocytes, which were identified as esterase positive cells, and Leu M3 cells were collected at higher counterflow rates and in the final fraction. The purity of monocytes in the final fraction was 81%. The oxidative metabolic activity ( @entity274 production) and non-specific esterase activity of individual monocytes was estimated in the analysis of functional heterogeneity of monocytes using flow cytometry. @entity21184 ( @entity21184 ) and @entity10156 (FDA) were used as indicators in the measurement of @entity274 generation and esterase activity. Intracellular generation of a fluorescence product ( @entity274 Production; average percentage of fluorescence positive cells) of monocytes in the stimulation of @entity4514 ( @entity4515 , 100 ng/ml) was greater in larger than smaller cells. @entity274 production gradually increased from 6% and 25-38% and 60% in the intermediate and final fractions respectively. Furthermore, the average fluorescence intensity of the large monocyte population in the final fraction was 1.13-1.31 fold more active than that of the smaller cells. Thus, the functional heterogeneity of @entity1 monocytes was further confirmed in the assays of @entity274 production exposed to @entity4515 and FDA hydrolysis using flow cytometry. Furthermore, the CCE system can isolate lymphocyte subsets and LGL.

title: Functional heterogeneity of XXXX monocytes--with a special reference to flow cytometric assays.

entities_list: @entity10156 :: ('MESH:C018506', 'Chemical') :: ['fluorescein diacetate']

entities_list: @entity21184 :: ('MESH:C029569', 'Chemical') :: ['DCFH-DA', "2',7'-dichlorofluorescein diacetate"]

entities_list: @entity4514 :: ('MESH:D013755', 'Chemical') :: ['phorbol myristate acetate']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: We describe, in a population-based cohort, the incidence of and factors associated with @entity260 ( @entity260 ) in pediatric-onset @entity29 . METHODS: Using the pediatric population-based EPIMAD Cohort (1988-2004), among 692 incident @entity29 cases, 128 @entity1 with @entity30 ( @entity30 ) and 25 with @entity31 ( @entity31 ) (22%) had undergone at least 1 major abdominal surgery at a median age of 16 years [interquartile range, Q1-Q3 = 14-17]. Factors associated with POC were assessed using Cox models. RESULTS: After a median postoperative follow-up of 8 years (3-12), 76 (49.7%) @entity1 had experienced at least 1 POC with a total of 113 complications. The frequency of severe POC (grade >2) was similar in @entity30 and @entity31 (28% of all complications versus 27%, P = 0.95). A total of 64 early @entity260 (within 30 d of surgery) were observed in 47 @entity1 (31%), with 33 being infectious and 31 noninfectious, higher in @entity31 than in @entity30 (25% of @entity1 with @entity30 versus 60% of @entity1 with @entity31 , P < 0.001). Forty-nine late @entity260 (>= 30 d) were observed in 37 @entity1 (24%). The occurrence of late POC was similar in @entity31 and @entity30 . The cumulative probability of POC was 31% (95% confidence interval, 24-39) at 1 month, 46% (38-54) at 1 year, and 48% (41-57) at 5 years. Multivariate analysis found that the @entity31 type was the only factor associated with early POC (hazard ratio = 2.9; 95% confidence interval, 1.6-5.4). CONCLUSIONS: One-half of the @entity1 with @entity29 had experienced at least 1 POC. Only @entity31 relative to @entity30 was significantly associated with an increased risk of early POC.

title: @entity260 in Pediatric XXXX : A Population-based Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'UC']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['POCs', 'postoperative complications']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['CD', "Crohn's disease"]

answer: @entity29 :: (MESH:D015212,Disease) :: ['Inflammatory Bowel Disease']


abstract: The goal of this study was to explore the correlation between education and the results of five @entity303 screening tests. In a study of 551 consecutively enrolled psychogeriatric day care attendants individual differences in education explained only very small portions of variance (< or = 0.63%) in four tests (visual recognition memory, orientation, category fluency and alternating sequences) of the Amsterdam @entity303 Screening Test, a standard neuropsychological battery. The only exception was graphical copying of two- or three-dimensional geometric designs, where education explained 6.25% of the variance in copying accuracy. The more education @entity1 had (from incomplete or complete primary education, through extended primary education, lower technical and vocational training, and secondary to higher education), the better their copying performance was. There was however one exception, in that @entity1 with secondary education copied designs significantly less accurately than @entity1 with lower technical and vocational training. Differences in copying accuracy of subjects with higher versus lower educational attainment were largest for @entity1 matched for high levels of cognitive function. More severe @entity73 attenuated education effects. Higher education did not protect against decline of copying performance as a consequence of increasing @entity73 . For each of three educational levels, premorbid copying performance was estimated by constructing a regression equation using an independent measure of cognitive functioning (in terms of visual recognition memory, orientation and category fluency) as the predictor variable. The results support the clinical utility of controlling for educational level when interpreting individual copying performance.

title: [Does education influence the results of the Amsterdam XXXX -Screening Test (ADS)?].

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['Dementia', 'dementia']

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment']

answer: @entity303 :: (MESH:D003704,Disease) :: ['Dementia']


abstract: BACKGROUND: Racial disparity is often identified as a factor in survival from @entity0 in the United States. Current data regarding survival in @entity1 treated in the Department of Defense Military Healthcare System is lacking. METHODS: The Department of Defense Automated Central Tumor Registry (ACTUR) was queried for all @entity1 diagnosed with @entity0 from January 1, 1996 through December 31, 2008. Statistical analyses evaluated demographics, surgical treatment, @entity5 stage, and survival rates. RESULTS: There were 8,890 @entity1 meeting inclusion criteria. @entity1 who were younger, Asian American (versus white or black), lower T and/or N stage had significantly improved survival rates. Interestingly, white and black @entity1 demonstrated similar survival in this study. @entity1 with a longer period of time between diagnosis and treatment had no decrement in survival. As would be expected, @entity1 with a longer recurrence free period enjoyed longer survival. CONCLUSIONS: Survival from early stage @entity0 is equivalent between white and black @entity1 in the Department of Defense Healthcare System. This finding is contrary to reports from our civilian counterparts and may be indicative of improved access to care and overall improved @entity5 surveillance. J. Surg. Oncol.    2015 Wiley Periodicals, Inc.

title: Racial disparity in survival from early XXXX in the department of defense healthcare system.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['Stage I or II breast cancer', 'breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: OBJECTIVES: @entity1241 ( @entity1241 ) are preferred over guaiac-based fecal occult blood testing as @entity14 ( @entity14 ) screening tool. However, hemoglobin (Hb) degradation over time may influence @entity1241 outcome. We therefore evaluated the effect of sample return time on @entity1241 performance characteristics in a population-based @entity14 screening trial. METHODS: A representative random sample of the Dutch population (n=17,677), aged 50-74 years, was invited for @entity1241 screening (OC-Sensor Micro; cutoff >=  50 ng Hb/ml). Sample return time was defined as the interval in days between fecal sampling and @entity1241 laboratory delivery. Moreover, a random sample of positive FITs were selected to be stored at room temperature and re-tested every 3-4 days. RESULTS: In total, 8,958 screenees fulfilled our inclusion criteria. The mean sample return time was 3 days (     3). Overall, 792 screenees (8.8%) had a positive test. Between the sample return time groups, the positivity rate (PR) varied between 7.7 and 9.0%. No statistically significant associations were found between PR or detection rate (DR) and the different sample return time groups (P value=0.84 and 0.76, respectively). For the laboratory experiment, 71 positive FITs were stored at room temperature and re-tested with standard intervals. The mean daily fecal Hb decrease was 5.88% per day (95% confidence interval 4.78-6.96%). None of the positive FITs became negative before 10 days after fecal sampling. CONCLUSIONS: This population-based @entity14 screening trial demonstrates that both the PR and DR of FITs do not decrease with prolonged sample return times up to 10 days. This means that a delay in sending the @entity1241 back to the laboratory, of up to at least 1 week, does not necessitate repeat sampling in case of a negative test result. These data support the use of @entity1241 -based screening as a reliable tool for nationwide @entity14 screening programs.

title: Are fecal immunochemical test characteristics influenced by sample return time? A population-based XXXX screening trial.

entities_list: @entity1241 :: ('MESH:D005242', 'Disease') :: ['Fecal immunochemical tests', 'FIT']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer']

answer: @entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']


abstract: BACKGROUND: @entity1652 spectrum disorder (NMOSD) and @entity15 ( @entity15 ) have a similar clinical phenotype but represent distinct diseases, requiring different therapies. MicroRNAs (miRNAs) are short non-coding RNAs whose expression profiles can serve as diagnostic biomarkers and which may be involved in the pathophysiology of @entity66 . Here, we analyzed miRNA profiles in serum and whole blood of @entity1 with NMOSD and @entity922 ( @entity922 )/relapsing-remitting @entity15 ( @entity3780 ) as well as healthy controls by next-generation sequencing (NGS). METHODS: MiRNA expression profiles were determined by NGS in sera of @entity1 with @entity3951 antibody-positive NMOSD (n   =   20), @entity922 / @entity3780 (n   =   20), and healthy controls (n   =   20) and in whole blood of @entity1 with NMOSD (n   =   11), @entity922 / @entity3780 (n   =   60), and healthy controls (n   =   43). Differentially expressed miRNAs were calculated by analysis of variance and t tests. All significance values were corrected for multiple testing. Selected miRNAs were validated in whole blood of @entity1 with NMOSD (n   =   18) and @entity922 / @entity3780 (n   =   19) by quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: None of 261 miRNAs detected in serum but 178 of 416 miRNAs detected in whole blood showed significantly different expression levels among the three groups. Pairwise comparisons revealed 115 (NMOSD vs. @entity922 / @entity3780 ), 141 (NMOSD vs. healthy controls), and 44 ( @entity922 / @entity3780 vs. healthy controls) miRNAs in whole blood with significantly different expression levels. qRT-PCR confirmed different expression levels in whole blood of @entity1 with NMOSD and @entity922 / @entity3780 for 9 out of 10 exemplarily chosen miRNAs. In silico enrichment analysis demonstrated an accumulation of altered miRNAs in NMOSD in particular in CD15(+) cells (i.e., neutrophils and eosinophils). CONCLUSIONS: This study identifies a set of miRNAs in whole blood, which may have the potential to discriminate NMOSD from @entity922 / @entity3780 and healthy controls. In contrast, miRNA profiles in serum do not appear to be promising diagnostic biomarkers for NMOSD. Enrichment of altered miRNAs in CD15(+) neutrophils and eosinophils, which were previously implicated in the pathophysiology of NMOSD, suggests that miRNAs could be involved in the regulation of these cells in NMOSD.

title: Next-generation sequencing identifies altered whole blood microRNAs in XXXX spectrum disorder which may permit discrimination from @entity15 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['neuroinflammatory diseases']

entities_list: @entity1652 :: ('MESH:D009471', 'Disease') :: ['Neuromyelitis optica']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['clinically isolated syndrome', 'CIS']

answer: @entity1652 :: (MESH:D009471,Disease) :: ['neuromyelitis optica']


abstract: Discovery of the B cell lymphoma gene 2 ( @entity588 gene) led to the concept that development of @entity5 required the simultaneous acquisition, not only of deregulated cell division, but also of resistance to programmed cell death or apoptosis. Apoptosis is arguably the common pathway to cell death resulting from a range of therapeutic initiatives, so that understanding the basis for the resistance of @entity5 cells to apoptosis may hold the key to development of new treatment initiatives. Much has already been learnt about the apoptotic pathways in @entity5 cells and proteins regulating these pathways. In most cells, apoptosis is dependent on the mitochondrial dependent pathway. This pathway is regulated by pro- and anti-apoptotic members of the @entity588 family, and manipulation of these proteins offers scope for a number of treatment initiatives. Effector caspases activated by the mitochondrial pathway or from death receptor signaling are under the control of the @entity23996 ( @entity23996 ) family. Certain proteins from mitochondrial can, however, competitively inhibit their binding to effector caspases. Information about the structure of these proteins has led to initiatives to develop therapeutic agents to block the @entity23996 family. In addition to development of selective agents based on these two ( @entity588 and @entity23996 ) protein families, much has been learnt about signal pathways that may regulate their activity. These in turn might provide additional approaches based on selective regulators of the signal pathways.

title: Overcoming resistance of XXXX cells to apoptosis.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer']

entities_list: @entity23996 :: ('84061', 'Gene') :: ['inhibitor of apoptosis protein', 'IAP']

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: We have examined the relative contribution of @entity3179 , activated coagulants, procoagulants and vessel wall damage in the pathogenesis of experimental @entity49 . Using a @entity3179 model in @entity95 , we found an inverse correlation between duration of @entity3179 and the amount of Contact Factor and Factor Xa required to produce a @entity3179 @entity715 . However, the slope of the dose-response curve for producing thrombi was different with these two coagulants. The infusion of Factor IX complex was also thrombogenic in this model despite prolonged circulation prior to @entity3179 , implying that high levels of multiple procoagulants may be thrombogenic. In contrast, Factor VIII concentrates or a purified Factor IX preparation did not give thrombi under these conditions. When the vessel wall was crushed mechanically, followed by restored blood flow and subsequent @entity3179 , there was essentially no formation of thrombi over the time course of the experiments. Scanning electron microscopy demonstrated that although the endothelium was swollen and damaged, there was usually no exposure of sub-endothelium and no adherence platelets. Where there was definite disruption of the endothelium, activated platelets could be seen adhering to the vessel wall. However, the blood in the segments remained fluid over a period of 30 min, despite the presence of adherent platelets. Our experiments demonstrated that the combination of vessel wall damage and @entity3179 was relatively ineffective in producing @entity49 . In contrast, high levels of zymogens or small amounts of activated clotting factors, combined with local @entity3179 , is a very effective thrombogenic stimulus in the venous system.

title: Experimental studies on XXXX : effect of coagulants, procoagulants and vessel contusion.

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

entities_list: @entity49 :: ('MESH:D019851', 'Disease') :: ['venous thrombosis']

entities_list: @entity3179 :: ('MESH:D014647', 'Disease') :: ['Wessler stasis', 'stasis']

answer: @entity49 :: (MESH:D019851,Disease) :: ['venous thrombosis']


abstract: BACKGROUND: @entity797 is a multifaceted microorganism known to act as a beneficial intestinal commensal bacterium. It is also a dreaded nosocomial pathogen causing life-threatening infections in hospitalised @entity1 . Isolates of a distinct MLST type ST40 represent the most frequent strain type of this species, distributed worldwide and originating from various sources (animal, @entity1 , environmental) and different conditions (colonisation/infection). Since enterococci are known to be highly recombinogenic we determined to analyse the microevolution and niche adaptation of this highly distributed clonal type. RESULTS: We compared a set of 42 ST40 isolates by assessing key molecular determinants, performing whole genome sequencing (WGS) and a number of phenotypic assays including resistance profiling, formation of biofilm and utilisation of @entity505 sources. We generated the first circular closed reference genome of an @entity797 isolate D32 of animal origin and compared it with the genomes of other reference strains. D32 was used as a template for detailed WGS comparisons of high-quality draft genomes of 14 ST40 isolates. Genomic and phylogenetic analyses suggest a high level of similarity regarding the core genome, also demonstrated by similar @entity505 utilisation patterns. Distribution of known and putative virulence-associated genes did not differentiate between ST40 strains from a commensal and clinical background or an animal or @entity1 source. Further analyses of mobile genetic elements (MGE) revealed genomic diversity owed to: (1) a modularly structured pathogenicity island; (2) a site-specifically integrated and previously unknown genomic island of 138 kb in two strains putatively involved in exopolysaccharide synthesis; and (3) isolate-specific plasmid and phage patterns. Moreover, we used different cell-biological and animal experiments to compare the isolate D32 with a closely related ST40 @entity884 isolate whose draft genome sequence was also generated. D32 generally showed a greater capacity of adherence to @entity1 cell lines and an increased pathogenic potential in various animal models in combination with an even faster growth in vivo (not in vitro). CONCLUSION: Molecular, genomic and phenotypic analysis of representative isolates of a major clone of @entity797 MLST ST40 revealed new insights into the microbiology of a commensal bacterium which can turn into a conditional pathogen.

title: Comprehensive molecular, genomic and phenotypic analysis of a major clone of XXXX MLST ST40.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity797 :: ('1351', 'Species') :: ['Enterococcus faecalis', 'E. faecalis']

entities_list: @entity884 :: ('MESH:D004696', 'Disease') :: ['endocarditis']

answer: @entity797 :: (1351,Species) :: ['Enterococcus faecalis']


abstract: OBJECTIVE: Juvenile @entity2631 is a chronic progressive @entity74 of the skin that causes @entity2319 and aesthetic damage. This study was undertaken to assess the safety and efficacy of @entity1499 ( @entity1500 ) in the treatment of juvenile @entity2631 . METHODS: In this double-blind study, @entity1 with active juvenile @entity2631 were randomized (2:1) to receive oral @entity1500 (15 mg/m  , maximum 20 mg) or placebo once weekly, for 12 months or until treatment failure. Both groups received oral @entity229 (1 mg/kg/day, maximum 50 mg) for the first 3 months. @entity75 was evaluated clinically, with infrared thermography and using a computerized scoring system with skin score rate ( @entity54909 ) evaluation. Response to treatment was defined as the absence of new lesions, @entity54909 , and a decrease in lesion temperature of at least 10% compared to baseline. Treatment failure was defined as the occurrence of new lesions, @entity54909 , or increased lesion temperature. All analyses were done on the intent-to-treat population. RESULTS: Of the 85 @entity1 screened, 70 (ages 6-17 years) were randomized (46 to the @entity1500 group, 24 to the placebo group). The mean disease duration was 2.3 years. After an initial response in all @entity1 , disease relapsed in 15 @entity1500 -treated @entity1 (32.6%) and 17 placebo-treated @entity1 (70.8%) (P < 0.005). New lesions appeared in 3 @entity1500 -treated @entity1 (6.5%) versus 4 placebo-treated @entity1 (16.7%). The mean @entity54909 decreased from 1 to 0.79 in the @entity1500 group and increased from 1 to 1.1 in the placebo group, and the mean @entity75 temperature decreased by 44.4% in the @entity1500 group versus 12.1% in the placebo group. Twenty-six @entity1 in the @entity1500 group (56.5%) and 11 @entity1 in the placebo group (45.8%) developed mild side effects related to treatment. None of the side effects were severe enough to necessitate treatment discontinuation. CONCLUSION: Our findings indicate that @entity1500 is efficacious in the treatment of juvenile @entity2631 and is well tolerated.

title: @entity1499 treatment in juvenile XXXX : a randomized, double-blind, placebo-controlled trial.

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion', 'A target lesion']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity2631 :: ('MESH:D012594', 'Disease') :: ['localized scleroderma']

entities_list: @entity2319 :: ('MESH:D003638', 'Disease') :: ['permanent disability']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['fibrotic disorder']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

answer: @entity2631 :: (MESH:D012594,Disease) :: ['localized scleroderma']


abstract: PURPOSE: Hyperthermic intraperitoneal chemotherapy (HIPEC) involves the continuous heating and circulation of chemotherapy throughout the abdominal cavity in an attempt to enhance @entity137 . Despite the potential of this chemotherapy procedure, there are scant anatomical temperature distribution studies reporting on this therapeutic process. @entity1 AND METHODS: We prospectively evaluated the temperature of select anatomical (e.g. upper abdominal, mid-abdominal and supra-pubic) sites in 11 advanced stage @entity43 @entity1 who were treated with consolidation HIPEC @entity3003 (AUC 10). The temperature of the aforementioned anatomical regions and the inflow/outflow tubing was measured at baseline and at 15-min intervals until the procedure's completion. RESULTS: The lowest observed mean composite temperature was 41.1     C at the supra-pubic site whereas the highest temperature was 42.6     C, in association with the inflow/outflow tubing. During the various time intervals we also ascertained that the lowest composite temperature was 40.9     C at baseline (i.e. time 0), whereas the highest value (41.8     C) occurred at multiple time periods (e.g. 15, 45 and 60   min). CONCLUSION: The HIPEC temperature variation amongst the various abdominal sites and time intervals was minimal. We also discerned that uniform temperature distribution throughout the abdominal cavity was facilitated when the abdomen was both maximally distended with fluid and a high flow rate was maintained.

title: Intra-abdominal temperature distribution during consolidation hyperthermic intraperitoneal chemotherapy with @entity3003 in the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer']

answer: @entity43 :: (MESH:D010051,Disease) :: ['advanced stage ovarian carcinoma']


abstract: BACKGROUND: The relevance of the temporal relationship between a unipolar electrogram (UEGM) and a bipolar electrogram (BEGM) in determining the site of origin (SOO) of focal @entity943 has been largely demonstrated. OBJECTIVE: We sought to demonstrate that a negative concordance in the initial forces of these EGMs is also helpful in predicting the SOO of @entity1540 ( @entity1540 ). METHODS: Mapping and radiofrequency (RF) ablation were performed in 41 @entity1 with symptomatic @entity1540 in the absence of structural @entity299 . Simultaneous recordings of the minimally filtered (0.5-500 Hz) UEGM and filtered BEGM (30-500 Hz) were analyzed at 247 mapping sites, where RF was attempted. EGMs of 63 mechanically induced @entity1540 were separately analyzed as a validation group. All ablation sites had a QS pattern in the UEGM. Acute PVC suppression was defined as a complete disappearance of @entity1540 after a 60-second pulse of RF. RESULTS: RF ablation obtained PVC suppression (RF+) in 33 of 247 sites (13.3%). A negative concordance pattern (NCP) during the initial 20 ms of both UEGM and BEGM was observed in 31 of 33 (94%) RF+ sites compared with 10 of 214 (4%)RF- sites (P < .0001). The NCP criterion demonstrated to be an additional powerful predictor of acute RF success with sensitivity, specificity, positive predictive value, and negative predictive value of 94%, 95%, 76%, and 99%, respectively. Similarly to RF+ sites, the NCP was observed in 60 of 63 sites (95.2%) in the mechanical PVC group. CONCLUSION: An NCP in both UEGM and BEGM may be an additional criterion that helps to localize the SOO of focal @entity943 .

title: Negative concordance pattern in bipolar and unipolar recordings: An additional mapping criterion to localize the site of origin of focal XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias', 'arrhythmias']

entities_list: @entity1540 :: ('MESH:D018879', 'Disease') :: ['premature ventricular contractions', 'PVCs', 'ventricular ectopic beats']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease']

answer: @entity943 :: (MESH:D001145,Disease) :: ['ventricular arrhythmias']


abstract: UNASSIGNED: Genome wide association studies (GWAS) for @entity2175 ( @entity2175 ) undertaken in European and Asian ancestry populations have yielded dozens of robustly associated loci. However, the genomics of @entity2175 remains largely understudied in sub-Saharan Africa (SSA), where rates of @entity2175 are increasing dramatically and where the environmental background is quite different than in these previous studies. Here, we evaluate 106 reported @entity2175 GWAS loci in continental Africans. We tested each of these SNPs, and SNPs in linkage disequilibrium (LD) with these index SNPs, for an association with @entity2175 in order to assess transferability and to fine map the loci leveraging the generally reduced LD of African genomes. The study included 1775 unrelated Africans (1035 @entity2175 cases, 740 controls; mean age 54 years; 59% female) enrolled in Nigeria, Ghana, and Kenya as part of the Africa America @entity6 (AADM) study. All samples were genotyped on the Affymetrix Axiom PanAFR SNP array. Forty-one of the tested loci showed transferability to this African sample (p < 0.05, same direction of effect), 11 at the exact reported SNP and 30 others at SNPs in LD with the reported SNP (after adjustment for the number of tested SNPs). @entity8405 SNP @entity8406 was the most significant locus in this study (p = 1.61 * 10(-8)). Most of the loci that showed transferability were successfully fine-mapped, i.e., localized to smaller haplotypes than in the original reports. The findings indicate that the genetic architecture of @entity2175 in SSA is characterized by several risk loci shared with non-African ancestral populations and that data from African populations may facilitate fine mapping of risk loci. The study provides an important resource for meta-analysis of African ancestry populations and transferability of novel loci.

title: Evaluation of Genome Wide Association Study Associated Type 2 XXXX Susceptibility Loci in Sub Saharan Africans.

entities_list: @entity2175 :: ('MESH:D003924', 'Disease') :: ['type 2 diabetes', 'T2D']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes Mellitus']

answer: @entity6 :: (MESH:D003920,Disease) :: ['Diabetes']


abstract: BACKGROUND: The @entity23905 is a mode of administration that provides greater security by allowing more accurate titration of the anesthetic agent. It leads to a better adaptation to the desired effects, and provide a great interest for the realization of anesthetic induction and the prediction of waking for a well- determined population. OBJECTIVE: The aim of our prospective study was to evaluate the feasibility of @entity23905 in @entity1 with @entity5845 undergoing laparoscopic surgery for @entity28 . METHODS: Thirty @entity1 were included in this study. Age and BMI means were 32 years and 49.31 kg / m2. Our protocol was proposed to associate an hypnotic agent ( @entity1875 ) to an opioid one ( @entity1937 ) using the technique of the @entity23905 , with respectively Schnider and Minto models. RESULTS: The induction protocol has brought good conditions for laryngoscopy with no @entity101 peak or desaturation episode. The period of unconsciousness was 89 seconds with an average target concentration of @entity1875 of 5.1 mg / ml. We also noted hemodynamic stability in 79% of @entity1 at induction. During both preparation phase and final installation of the @entity1 , a low ERC to 2 hg / ml was consistent with a suitable hemodynami profile. We obtained hemodynamic stability by adapting target concentration of @entity1937 at different operating times ( @entity954 : 3.64 hg / ml, insufflation of the peritoneum: 5.37 hg / ml, jejuno-jejunal resection @entity254 : 9 hg / ml, gastric resection and gastrojejunal @entity254 : 14.2 hg / ml). During this period, no episodes of @entity1168 or @entity551 were noticed. During the recovery phase and while doing the distribution of CEP and CER according to the BMI of @entity1 , we identified two groups: Group 1 (BMI <49 kg / m2): fast time extubation (11 min) and target concentrations of @entity1875 and @entity1937 respectively at 1.3 mg / ml and 1.25 hg / ml which is similar to most publications on this subject and Group 2 (BMI> 49 kg / m2): time-delayed extubation (23 min) with very low values of CEP and CER inconsistent with the literature data.

title: [Target-controlled intravenous anesthesia during laparoscopic surgery for XXXX ].

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertensive']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']

entities_list: @entity254 :: ('MESH:C563598', 'Disease') :: ['anastomosis']

entities_list: @entity5845 :: ('MESH:D009767', 'Disease') :: ['morbid obesity']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol']

entities_list: @entity954 :: ('MESH:D016063', 'Disease') :: ['Surgical incision']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['hypotension']

entities_list: @entity1168 :: ('MESH:D001919', 'Disease') :: ['bradycardia']

entities_list: @entity1937 :: ('MESH:C071741', 'Chemical') :: ['remifentanil']

answer: @entity28 :: (MESH:D009765,Disease) :: ['obesity']


abstract: OBJECTIVE: To observe the expression of p- @entity12220 mitogen-activated protein kinase in lung tissues of @entity647 @entity35 model induced by lipopolysaccharide (LPS) and to explore the protective effects of @entity2493 (MT) in lung tissues in @entity35 . METHODS: Seventy-two @entity35 was randomly assigned to three groups, control group, LPS group and LPS + MT group. @entity35 model of ALI was established by instilling LPS intratracheally. We used immunohistochemical SP and Western blot method to detect the expression of p- @entity12220 mitogen-activated protein kinase in lung tissues and used light microscope to observe morphological changes. RESULTS: There were rare p- @entity12220 mitogen-activated protein kinase positive cells scattered in alveolar and airway epithelial cells in control group (P < 0.01). The positive p- @entity12220 mitogen-activated protein kinase cells in LPS group increased obviously than those in control group (P < 0.01), and were mainly distributed in infiltrative inflammatory cells, airway epithelial cells, alveolar epithelial cells and pleurames epithelial cells. In MT group, the p- @entity12220 mitogen-activated protein kinase positive cells in airway and lung tissues were much less than those in the LPS group (P < 0.05). The Western blot results were consistent with those of immunohistochemical method. CONCLUSION: The expression of p- @entity12220 mitogen-activated protein kinase increases in alveolar and airway epithelial cells in @entity647 @entity35 models induced by LPS. The activation of p- @entity12220 mitogen-activated protein kinase is found in most lung tissues, suggesting that p- @entity12220 mitogen-activated protein kinase participates in the signal transduction in inflammatory and noninflammatory cells. MT is an effective antioxidant, which relieves the @entity32 in @entity647 @entity35 , possibly through the inhibition of the pathway of @entity12220 MAPK over activation.

title: [Protective effects of @entity2493 in @entity647 XXXX caused by LPS].

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2493 :: ('MESH:D008550', 'Chemical') :: ['melatonin']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: The vanilloid receptor protein ( @entity5510 ) is a well-characterised integrator of noxious stimuli in peripheral sensory neurones. There is evidence for the presence of @entity5510 in the central nervous system, but little information as to its role there. In this study we have examined the actions of agonists for @entity5510 receptors in the @entity35 locus coeruleus (LC), using whole-cell patch-clamp recordings from acutely isolated neurones and neurones in slices. Superfusion with @entity2951 resulted in a concentration-dependent increase in the frequency of isolated miniature excitatory postsynaptic currents (mEPSCs) in LC neurones. The mean amplitude of the mEPSCs was not affected by @entity2951 . The effects of @entity2951 (1 microM) were abolished by the @entity5510 receptor antagonists @entity4413 (10 microM) and iodoresiniferatoxin (300 nM). Removal of extracellular @entity141 abolished the @entity2951 -induced increase in frequency of mEPSCs. @entity2951 superfusion had no consistent effects on evoked excitatory postsynaptic currents. @entity2951 superfusion also resulted in the release of an adrenoceptor agonist in the LC but did not affect the membrane currents of acutely isolated LC neurones. These data demonstrate that the @entity5510 receptor appears to be located presynaptically on afferents to the LC, and that activation of @entity5510 may serve to potentiate the release of @entity2227 and @entity1425 / @entity1063 in this brain region.

title: @entity2951 activation of glutamatergic synaptic transmission in the XXXX locus coeruleus in vitro.

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate']

entities_list: @entity2951 :: ('MESH:D002211', 'Chemical') :: ['Capsaicin', 'capsaicin']

entities_list: @entity1425 :: ('MESH:D004837', 'Chemical') :: ['adrenaline']

entities_list: @entity4413 :: ('MESH:C071423', 'Chemical') :: ['capsazepine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: UNASSIGNED: @entity1582 is a haematological @entity5 whose care is spread over several specialities and provided by centres that various sizes, which raises the issue of equal opportunities in care access. Incident cases of @entity1582 between 2008 and 2010 were exhaustively identified by the Poitou-Charentes Cancer Registry. To ascertain the quality of care, the diagnosis, staging, and treatment administered were compared to international recommendations. Three hundred and sixty-seven @entity1 were included. The diagnostic procedure exhibited 98% compliance, the staging 58%, and treatment 89%. Concerning diagnostic and staging, non-compliance with recommendations was associated to the failure to perform collegiate case assessments in multidisciplinary team (MDT) meetings [OR 2.15 (1.15-4.04)], care provided at a secondary centre, and a distance between home and the centre of 5-25  km [2.16 (1.06-4.40)] and 25-50  km [2.86 (1.37-6.01)]. Regarding treatment, non-compliance with recommendations was associated with care provided at a secondary centre [5.28 (2.03-13.75)]. Finally, diagnosis, staging and treatment quality improved over time. This study underlines the need to improve the organisation of the healthcare offer, so that @entity1 can receive the best possible care. MDT seems to be the main means to improve quality of care.

title: XXXX : the quality of care is linked to geographical and organisational determinants. A study in a French registry.

entities_list: @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma', 'Multiple myeloma']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy']

answer: @entity1582 :: (MESH:D009101,Disease) :: ['Multiple myeloma']